Honma N, Takubo K, Akiyama F, Kasumi F, Sawabe M, Arai T, Hosoi T, Yoshimura N, Harada N, Younes M, Sakamoto G
Research Team for Geriatric Diseases, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Histopathology. 2007 Mar;50(4):425-33. doi: 10.1111/j.1365-2559.2007.02636.x.
Apocrine carcinoma of the breast seldom expresses oestrogen receptors (ER) or progesterone receptors (PR), but frequently expresses androgen receptors (AR). Because of this unusual hormone receptor status, it has been suggested that oestrogens have a less important role in the pathogenesis of apocrine carcinoma. The ER status of apocrine carcinoma has been studied for one kind of ER, the classic receptor now named ER-alpha; however, the status of ER-beta, a secondary oestrogen receptor, has not been examined systematically in apocrine carcinoma. The aim was to study ER-beta status in apocrine carcinoma.
The expression of ER-beta was examined immunohistochemically in 48 apocrine carcinomas and compared with clinicopathological factors and ER-alpha, PR and AR status. ER-beta positivity was observed in 35 cases (73%), regardless of any clinicopathological factors or the status of other receptors. The results of ER-beta mRNA analysis supported the immunohistochemical results.
The significance of oestrogens in apocrine carcinoma should not be dismissed at present when the role of ER-beta remains to be determined. Studying the action of oestrogen or antioestrogen in apocrine carcinoma may reveal a role for ER-beta independent of ER-alpha and raise the potential of hormonal therapy for these tumours.
乳腺大汗腺癌很少表达雌激素受体(ER)或孕激素受体(PR),但经常表达雄激素受体(AR)。鉴于这种不寻常的激素受体状态,有人提出雌激素在大汗腺癌的发病机制中作用较小。对于大汗腺癌的ER状态,已针对一种ER(即现在命名为ER-α的经典受体)进行了研究;然而,作为次要雌激素受体的ER-β在大汗腺癌中的状态尚未得到系统研究。目的是研究大汗腺癌中ER-β的状态。
采用免疫组织化学方法检测48例大汗腺癌中ER-β的表达,并与临床病理因素以及ER-α、PR和AR状态进行比较。在35例(73%)病例中观察到ER-β阳性,与任何临床病理因素或其他受体状态无关。ER-β mRNA分析结果支持免疫组织化学结果。
鉴于ER-β的作用仍有待确定,目前不应忽视雌激素在大汗腺癌中的意义。研究雌激素或抗雌激素在大汗腺癌中的作用可能揭示ER-β独立于ER-α的作用,并提高这些肿瘤激素治疗的潜力。